iTeos Therapeutics to Participate in Upcoming September Investor Conferences
September 01 2021 - 7:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immune-oncology
therapeutics for patients, today announced that company management
will participate in five upcoming virtual investor conferences in
September:
- KBC Securities Life Sciences ConferenceFormat:
Management one-on-onesDate: September 7, 2021
- Wells Fargo Virtual Healthcare Conference
Format: Management one-on-onesDate: September 9-10, 2021
- Morgan Stanley 19th
Annual Global Healthcare ConferenceFormat:
Management one-on-onesDate: September 9-10 and 13-15, 2021
- H.C. Wainwright 23rd
Annual Global Investment Conference Format: On
demand presentation by Michel Detheux, Ph.D., President and Chief
Executive OfficerDate/Time: Monday, September 13, 2021 at 7:00 a.m.
ET
- Cantor Fitzgerald Global Healthcare
ConferenceFormat: Live presentation by Michel Detheux,
Ph.D., President and Chief Executive OfficerDate/Time: Monday,
September 27, 2021 at 2:40 p.m. ET
Audio webcasts of the presentations will be available on the
Investor section of the company’s website at
https://www.iteostherapeutics.com. An archived replay will be
available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.iTeos
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
The Company’s innovative pipeline includes two clinical-stage
programs targeting novel, validated immuno-oncology. The initial
antibody product candidate, EOS-448, is a high affinity, potent,
anti-TIGIT antibody with a functional Fc domain, designed to
enhance the anti-tumor response through a multifaceted immune
modulatory mechanism. An open-label Phase 1 clinical trial of
EOS-448 is ongoing in adult cancer patients with advanced solid
tumors with preliminary data indicating preliminary clinical
activity as a monotherapy and a favorable tolerability profile. The
Company is also advancing inupadenant, a first insurmountable
adenosine A2A receptor antagonist in clinical development tailored
to overcome cancer immunosuppression. iTeos is conducting an
open-label multi-arm Phase 1/2a clinical trial of inupadenant in
adult cancer patients with advanced solid tumors. Preliminary
results indicate encouraging single-agent activity as well as the
identification of a potential predictive biomarker. iTeos
Therapeutics is headquartered in Cambridge, MA with a research
center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:Ryan BakeriTeos Therapeutics,
Inc.Ryan.Baker@iteostherapeutics.com
Media Contact: media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Apr 2023 to Apr 2024